<DOC>
	<DOCNO>NCT02446847</DOCNO>
	<brief_summary>This study evaluate effect two infusion 3BNC117 prevent delay rebound viral load brief treatment interruption standard ART safety brief analytical interruption antiretroviral therapy .</brief_summary>
	<brief_title>3BNC117 Monoclonal Antibody HIV-infected Subjects During Treatment Interruption</brief_title>
	<detailed_description>The propose study Phase II , open label study evaluate safety antiretroviral activity two four infusion 3BNC117 HIV-infected subject combination ART brief analytical treatment interruption . After meet enrollment criterion sixteen subject 3BNC117 sensitive virus ( &lt; 2μg/ml IC50 ) receive two ( Group A ) four ( Group B ) intravenous infusion 3BNC117 , administer 30 mg/kg . In dose group , antiretroviral therapy discontinue 2 day first 3BNC117 infusion ( day 2 ) week 12 . Combination ART resume week 12 . ART resume sooner plasma HIV-1 RNA level ≥ 200 copies/ml CD4+ count drop &lt; 350 cells/μl either result confirm upon repeat measurement . Participants follow weekly week 12 safety assessment monitor plasma HIV-1 RNA level ( viral load ) . CD4+ T cell count monitor every 2 week week 12 . Participants may remain antiretroviral therapy week 12 , weekly viral load monitoring , viral rebound occur week 12 . Participants follow total 36 week .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Age 18 65 HIV1 infection confirm ELISA immunoblot . Plasma HIV1 RNA &lt; 50 copies/ml least 12 month combination ART &lt; 20 copies/ml screen visit . [ Note : One two viral blip &lt; 200 copies/mL prior enrollment permit preceded followed test result show VL le equal 50 copies/mL ARV regimen . ] 3BNC117 sensitivity ( IC50 &lt; 2 μg/ml ) subject derive HIV1 virus isolates . These isolated protocol MCA823 coculture subject PBMCs HIVuninfected donor PBMCs follow vitro neutralization assay previously describe Current CD4 cell count &gt; 500 cells/μl prior CD4 cell count &lt; 200 cells/μl . Willing interrupt antiretroviral treatment 12 week , viral rebound occur . If sexually active male female , participate sexual activity could lead pregnancy use effective method contraception throughout study period . Subjects also agree use male female condom time pause HIV medication . If NNRTIbased regimen willing switch 4 week dolutegravir . Have history AIDSdefining illness within 1 year prior enrollment History systemic corticosteroid , immunosuppressive anticancer , medication consider significant trial physician within last 6 month ; Chronic hepatitis B hepatitis C ; Patient report , chart history , significant coronary artery disease , myocardial infarction , percutaneous coronary intervention placement cardiac stent ; Patient report , chart history , diabetes type 1 2 and/or current use insulin oral hypoglycemic medication ; Uncontrolled hypertension , define systolic blood pressure &gt; 180 and/or diastolic blood pressure &gt; 120 , presence absence antihypertensive medication ; Any clinically significant acute chronic medical condition , autoimmune disease , opinion investigator would preclude participation ; Current cigarette use excess 1 pack per day ; Laboratory abnormalities parameter list : Absolute neutrophil count ≤1,000 Hemoglobin ≤ 10 gm/dL Platelet count ≤125,000 ALT ≥ 2.0 x ULN AST ≥ 2.0 x ULN Total bilirubin ≥ 1.5 ULN Creatinine ≥ 1.1 x ULN Coagulation parameter ≥ 1.5 x ULN ; Current antiretroviral regimen include either maraviroc enfuvirtide ; Pregnancy lactation ; Any vaccination within 14 day prior 3BNC117 administration ; Receipt monoclonal antibody therapy kind past ; Participation another clinical study investigational product currently within past 12 week , expect participation study . History resistance two antiretroviral drug class</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>3BNC117</keyword>
	<keyword>Broadly neutralize antibody</keyword>
</DOC>